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The spatial correlations between the brain’s default mode network (DMN) and the brain regions known to develop
pathophysiology in Alzheimer’s disease (AD) have recently attracted much attention. In this paper, we compare results of different
functional and structural imaging modalities, including MRI and PET, and highlight different patterns of anomalies observed
within the DMN. Multitracer PET imaging in subjects with and without dementia has demonstrated that [C-11]PIB- and [F-
18]FDDNP-binding patterns in patients with AD overlap within nodes of the brain’s default network including the prefrontal,
lateral parietal, lateral temporal, and posterior cingulate cortices, with the exception of the medial temporal cortex (especially,
the hippocampus) where significant discrepancy between increased [F-18]FDDNP binding and negligible [C-11]PIB-binding was
observed. [F-18]FDDNP binding in themedial temporal cortex—a key constituent of the DMN—coincides with both the presence
of amyloid and tau pathology, and also with cortical areas with maximal atrophy as demonstrated by T1-weighted MR imaging of
AD patients.
1. Introduction
In 2001, the default mode network (DMN) was first pro-
posed as an interconnected set of brain regions that is active
when the brain is in a resting state and typically deactivated
during memory encoding and other cognitively demanding
tasks focused on processing of external stimuli [1]. The DMN
includes the dorsal and ventral medial prefrontal cortices,
medial and lateral parietal cortex, and parts of themedial and
lateral temporal cortices.
It has been suggested that the DMN consists of two
subsystems that converge on two core regions: anterior
medial prefrontal cortex and posterior cingulate cortex. The
two subsystems, dorsal medial prefrontal cortex subsystem
(consisting of dorsal medial prefrontal cortex, temporopari-
etal junction, lateral temporal cortex, and temporal pole)
and medial temporal cortical subsystem (consisting of
ventral medial prefrontal cortex, posterior inferior parietal
lobule, retrosplenial cortex, parahippocampal cortex, and
hippocampal formation) may be activated simultaneously
or separately during these tasks [2]. Tasks during which the
DMN is activated include, among others, autobiographical
memory, thinking about one’s future, theory of mind, self-
referential and affective decision-making [2].
Alzheimer’s disease (AD) affects many aspects of cog-
nitive function, in particular memory, attention, visuospa-
tial orientation, and language. These changes in multiple
domains point to widespread abnormalities in brain circuitry
at more advanced stages of disease [3]. Early symptomatol-
ogy of AD has been linked to changes in the default mode
network based on glucose metabolism and blood flow PET
and SPECT measurements and later with fMRI experiments
(reviewed by [4]). As a result, the default network rapidly
became the target of extensive research in the AD field [4–
9]. In addition to extensive cortical neuronal loss, AD is also
defined by the presence of brain amyloid pathology (amyloid
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plaques) and tau pathology (neurofibrillary tangles) [10, 11],
postmortem detection of which is required for the definitive
diagnosis of AD.
In this paper, we compare results of different functional
and structural imaging modalities used in AD imaging
including T1-wighted MR imaging, fMRI, 2-deoxy-2-[F-
18]fluoro-D-glucose ([F-18]FDG)-PET, 6-hydroxy-2-(4
′
-
([C-11]methylamino)phenyl)benzothiazole ([C-11]PIB)-
PET, and 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-
2-naphthyl}ethylidene)malononitrile ([F-18]FDDNP)-PET
imaging from the perspective of the brain’s DMN.
Imaging results across imaging modalities probing different
pathophysiological changes in AD show different patterns of
anomalies observed within the DMN. For example, declines
in [F-18]FDG PET measures of glucose metabolism in
posterior cingulate gyrus at the earliest presymptomatic
stages of AD and progression to parietal and lateral
temporal cortices in mild AD [12] were early observed,
yet these functional changes cannot be attributed only to
cortical atrophy in these regions, but also to deficits in
neuronal projections resulting from pathology deposition
and neuronal degeneration in the medial temporal cortex
[13]. This is also shown in the effect of entorhinal and
rhinal lesioning on posterior cingulate regional cerebral
glucose utilization in baboons [14]. Robust atrophy as
well as significantly increased [F-18]FDDNP binding
was found within the medial temporal cortex and other
parietal and temporal regions at early stages of AD [15–18].
[F-18]FDDNP is the first PET molecular imaging probe
successfully applied for in vivo visualization of Alzheimer’s
disease pathology in the brain of living AD patients with a
pattern of increased binding in the brain areas known to
contain both amyloid plaques and neurofibrillary tangles
[13, 16, 19, 20]. These brain areas include medial temporal
and lateral temporal cortices, posterior cingulate gyrus,
parietal and frontal cortices, all of which are involved in the
DMN. Similarly several studies have correlated [C-11]PIB
binding with the anatomical substrates of the DMN [4, 21–
23] and have found increased [C-11]PIB binding in several,
but not all, DMN brain regions. Recently, multitracer PET
imaging using both [F-18]FDDNP and [C-11]PIB in the
same subjects with and without dementia have provided
important information on clear and meaningful similarities
and differences in topographical distribution between
[C-11]PIB-PET and [F-18]FDDNP-PET images [24–27].
2. Emergence of the Default Mode Network
Raichle, Gusnard, and colleagues introduced the concept of
DMN with three fMRI papers in 2001 [1, 28, 29]. Their
papers directly considered the empirical and theoretical
implications of defining baseline states and what the specific
pattern of activity in the default mode network might
represent [4]. Prior to the availability of fMRI the activation
studies using [O-15]H2O PET (and other perfusion agents)
have been used to study activity patterns of the brain in
the resting state. Figure 1 shows the common, default mode
activity in young adults measured by [O-15]H2O PET (see
Default activity
Figure 1: The brain’s default network was originally identified in a
meta-analysis that mapped brain regions more active in passive as
compared to active tasks (often referred to as task-induced deacti-
vation). The displayed [O-15]H2O positron emission tomography
(PET) data include nine studies (132 young adults) from Shulman
et al. [30] (reanalyzed in [21]). Images show the medial and lateral
surface of the left hemisphere using a population-averaged surface
representation to take into account between-subject variability in
sulcal anatomy. Blue represents regions most active in passive task
settings. Adapted and reprinted with permission from Buckner et al.
[4, 21] [Copyright (2005) Journal of Neuroscience].
[4, 21, 30] for detail). These results point to a wide network
of regions activated in the default state and includes the
precuneus (the portion of the parietal cortex caudal to the
paracentral lobule) extending into posterior cingulate and
retrosplenial cortex, as well as inferior lateral parietal regions,
frontal regions along the midline, medial, and temporal
cortex [4, 21, 31–33].
3. Disruption of the Default Network in AD
3.1. MRI Measures of Atrophy. A variety of pathological
processes including neuronal loss, synaptic loss, and loss of
projections contribute to gray matter atrophy which spreads
across the brain in AD with the disease progression dis-
rupting neuronal circuits involved in the DMN prominently
including the medial temporal cortex [17, 21, 22, 34, 35].
The temporal trajectory of cortical atrophy was studied by
Whitwell et al. [18] in a longitudinal MRI study of atrophy
in amnesticMCI (aMCI) subjects who progressed to AD. The
initial pattern of grey matter loss in the aMCI subject scans
3 years prior to the diagnosis of AD was focused primarily in
the medial temporal cortex, including the amygdala, anterior
hippocampus and entorhinal cortex, with some additional
involvement of the fusiform gyrus,. The extent and magni-
tude of cerebral atrophy in these patients further progressed
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Figure 2: Patterns of grey matter atrophy in patients with AD
compared with age-matched control group. The results are shown
on a 3D surface render (top) and overlaid on representative axial,
coronal and sagittal slices (bottom). L: left; R: right. Adapted and
reprinted with permission from Whitwell et al. [18] [Copyright
(2005) Brain].
over the following two years with atrophy in the medial
temporal cortex spreading to middle temporal gyrus, and
extended into more posterior regions of the temporal cortex
to include the entire extent of the hippocampus and partial
involvement of the parietal cortex. By the time the subjects
had progressed to a clinical diagnosis of AD the pattern of
grey matter atrophy had becomemore widespread withmore
severe involvement of the medial temporal cortex and the
temporoparietal association cortices and, for the first time,
substantial involvement of the frontal cortex (see Figure 2).
Accelerated atrophy is also observed in the posterior
cingulate gyrus, one of the core regions of DMN [2] and
an area with the earliest decline in glucose utilization in
the preclinical stages of AD [12]. This implies that the early
functional abnormalities and structural changes of neuronal
circuitry in the default mode network only involve a subset
of DMN core regions [4, 21] to progress later to other areas
of the network.
3.2. Functional MRI. Recently, functional changes in the
default mode network have been explored with fMRI in AD
using both analysis of task-induced deactivation [36, 37] and
analysis of intrinsic activity correlations [33, 37–39].
Thus, by all measures the default mode network appears
disrupted in AD, including prominently the medial temporal
cortex subsystem and posterior cingulate area [4].
4. PET Imaging of Amyloidosis and
Tauopathy in AD
4.1. [F-18]FDDNP-PET in AD. Beta-amyloid plaques and
neurofibrillary tangles are the two most common neu-
ropathological hallmarks of Alzheimer’s disease and they
appear in distinctive progressive temporal and spatial pat-
terns of cortical pathology evolution during the disease
progression [11]. [F-18]FDDNP is known to bind to amyloid
plaques as well as neurofibrillary tangles in vitro [20]. Post
mortem neuropathological studies of AD patients who pre-
viously received [F-18]FDDNP-PET scans show close match-
ing of in vitro immunohistochemical determined pattern of
plaque and tangle distribution in the brain regions with
imaging results [16]. [F-18]FDDNP PET-binding patterns of
subjects with mild cognitive impairment and AD patients
[16] is progressive. Initially increased medial temporal cortex
binding in controls at risk and MCI subjects is followed
by a variable and progressive pattern of binding in one or
more of other cortical areas including posterior cingulate
gyrus. In contrast, more advanced AD patients had a pattern
of elevated [F-18]FDDNP binding in prefrontal, parietal,
posterior cingulate, lateral temporal and medial temporal
cortices areas [15, 16, 24]. These results in living humans
clearly point at the medial temporal cortex as being the
area with the earliest pathological lesion formation which is
in accordance with neuropathology findings [11]. Figure 3
shows three-dimensional cortical surface projection images
of [F-18]FDDNP-PET scans from a representative patient
with AD.
4.2. [C-11]PIB-PET in AD. PET imaging studies with [C-
11]PIB, which has been suggested to bind to amyloid plaques
only [40, 41], show a single pattern of [C-11]PIB binding
in the prefrontal, lateral parietal, posterior cingulate, lateral
temporal cortices and precuneus [40] at all levels of cognitive
impairment, including AD, a subset of MCI subjects and
even some cognitively normal controls. This pattern of [C-
11]PIB cortical uptake was correlated with the DMN by
Buckner et al. [21] who noticed overlap of DMN and [C-
11]PIB-binding pattern in cortical areas with exception of
themedial temporal cortex which include both hippocampus
and parahippocampal gyrus (see Figure 4). When compared
with the patterns of known beta-amyloid deposition in
AD [11, 42, 43], this lack of [C-11]PIB binding in the
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Figure 3: Three-dimensional cortical surface projection images of
[F-18]FDDNP-PET scans from a patient with AD. Lateral (upper)
and medial (lower) brain surfaces are shown. Warmer colors
indicate higher numbers of plaques and tangles. Adapted and
reprinted with permission from Small et al. [16] [Copyright (2008)
Lancet Neurology].
hippocampus and neocortical areas of medial temporal
cortex (entorhinal, parahippocampal, rhinal, and perirhinal
cortices) points to the most significant mismatch between
beta-amyloid pathology and [C-11]PIB binding. Indeed
multiple contradictory [C-11]PIB-binding results in humans
have been reported [44] and recent work demonstrating that
[C-11]PIB brain accumulation may be at least in part medi-
ated by [C-11]PIB sulfation via estrogen sulfotransferase [45]
has cast doubts on the purported human amyloid specificity
of [C-11]PIB.
It may be possible that other factors, like cortical atrophy
and/or low distribution of amyloid aggregates may con-
tribute to the underestimation of [C-11]PIB accumulation
in medial temporal lobe (MTL). Indeed, topographical
differences in the distribution of senile plaques (SP) and
neurofibrillary tangles (NFT) have been noted in AD, with
lower densities of SP in limbic areas of MTL, such as
hippocampus and subiculum, which are more affected by
neurofibrillary tangle pathology [10]. Yet in other areas of
medial temporal lobe, such as entorhinal, perirhinal, and
rhinal cortices as well as parahippocampal gyrus, β-amyloid
plaque densities (both diffuse and neuritic plaques) reach
levels observed in lateral temporal lobe and other cortical
areas even in subjects without clinically manifested dementia
and only limited atrophy [43]. Thus, even though some
partial volume effects are expected, it is unlikely that [C-
11]PIB negligible binding in MTL at all levels of cognitive
impairment is entirely due to the combined effects of low
Figure 4: Surface maps indicating the pattern of [C-11]PIB
binding obtained with 10 patients with clinical Alzheimer’s disease
compared with 29 healthy older control subjects. Adapted and
reprinted with permission from Buckner et al. [21] [Copyright
(2005) Journal of Neuroscience].
β-amyloid plaque densities and atrophy. If so, one would
also expect a similar drastic effect of MTL atrophy with the
[F-18]FDDNP signal in the same patients, and this is not
observed (Figures 5 and 6).
5. [F-18]FDDNP- and [C-11]PIB-PET
Comparison in the Same AD Patients
Postmortem pathological studies of AD brains demonstrated
that the distribution of neuritic plaques may present sig-
nificant intersubject variability. [10, 11]. To minimize this
effect and to compare more accurately binding patterns
of both imaging probes, comparison of [F-18]FDDNP and
[C-11]PIB binding in the same AD subjects is necessary.
Recently, a comparative multitracer PET imaging study using
both [F-18]FDDNP and [C-11]PIB has been performed in
control subjects and patients with AD [24, 25]. These studies
demonstrate that in AD both probes show widespread
cortical uptake within the areas of the DMN including the
prefrontal cortex, lateral parietal, lateral temporal cortex,
and posterior cingulate cortices (Figure 5). However, these
studies also demonstrate the critical difference between [C-
11]PIB and [F-18]FDDNP binding in the medial temporal
cortex, where [F-18]FDDNP is high and [C-11]PIB binding
is negligible in the same AD subjects.
To highlight the different binding pattern of [F-
18]FDDNP and [C-11]PIB in the medial temporal cortex,
the subtracted PET imaging of [F-18]FDDNP minus [C-
11]PIB in the same subjects with AD was calculated. Figure 6
demonstrates that the medial temporal cortex was the most
significant differential brain region in the voxel mapping of
the subtracted PET imaging.
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Figure 5: Comparison of [C-11]PIB SPM t-map image (red) and
[F-18]FDDNP SPM t-map image (green) obtained with 10 AD
patients compared with 10 healthy age-matched control subjects
(P < .05, uncorrected, k = 100). The yellow area represents the area
where the [C-11]PIB SPM t-map (red) and [F-18]FDDNP SPM t-
map (green) overlapped. Adapted and reprinted with permission
from Shin et al. [25] [Copyright (2010) Neuroimage].
6. Default Mode Network andMedial
Temporal Cortex
One has to approach with cautious interpretation of imaging
data across the modalities in DMN since comparing activity
with structural changes may lead to erroneous conclusions
regarding AD and its progression. Resting state fMRI, [O-
15]H2O PET, and [F-18]FDG PET give us information about
the activity of DMN during a variety of thought processes
considered as resting state in healthy subjects and in AD
patients. Functional changes in specific DMN nodes may
result from the pathology present in the nodes themselves or
can reflect pathological changes in connectivity of the circuits
leading to and from the specific node. It is not surprising
that neuropathological structural changes present at early
stages of AD evolution (MRI atrophy in the medial temporal
cortex) may not overlap with functional changes entirely ([F-
18]FDG decline in posterior cingulate gyrus). [F-18]FDG
decline does reflect changes in functional activity of neuronal
terminals (i.e., in posterior cingulate gyrus) caused by
neuropathology in their cell bodies (i.e., in hippocampus and
other medial temporal cortex substructures).
Comparison of [F-18]FDDNP and [C-11]PIB-binding
patterns at early stages and late stages of AD shows stark
difference between the immutable pattern of [C-11]PIB-
binding patterns [46] and evolution of [F-18]FDDNP-
binding with disease progression from initial localization in
themedial temporal cortex to the widespread cortical pattern
found in AD as expected from autopsy determinations. If
one accepts the hypothesis that [C-11]PIB-binding reflects
the level of beta-amyloid plaques in vivo then the obvious
lack of [C-11]PIB-binding to the medial temporal cortex,
an area with early and abundant deposition of amyloid
plaques [11, 43] raises the question about the validity of
this hypothesis. Although correlation of [C-11]PIB-binding
pattern in AD and increased levels of regional consumption
of glucose via glycolysis have been noted, there was poor
correlation between the total level of glucose utilization
(indicative of the remaining cell density and their func-
tional activity in the affected areas) and the levels of [C-
11]PIB-binding. Longitudinal [C-11]PIB and [F-18]FDG
PET studies in AD [47, 48] have shown progressive cortical
metabolic decline, as measured with [F-18]FDG, in parallel
with cognitive function, but no significant changes in [C-
11]PIB binding levels or binding pattern over time were
observed.
Early pathology observations have revealed that AD
affects only a subset of neurons in regional and laminar
specific neuronal systems [49] and that AD is a discon-
nection syndrome with damage to the entorhinal cortex
and/or subiculum which effectively disconnects hippocam-
pal formation from the rest of the neocortex. Subsequent
progression of the disease occurs in a stepwise fashion along
cortico-cortical connections [50]. Large cross-sectional stud-
ies have revealed that cortical neurofibrillary tangle den-
sities and not amyloid deposits are the best correlates
of the severity of dementia, neuronal loss, and atrophy
[51].
These pathology observations support the hypothesis
that DMN and its subsystems are affected early in AD with
neurofibrillary tangles, neuronal loss, and atrophy in the
medial temporal cortex and earliest metabolic changes in
posterior cingulate area. Both areas are highly connected
with other cortical and subcortical regions and are thus
excellent starting points for spread of pathological changes
as hypothesized by de Lacourte and White III [50].
7. Conclusions
The spatial correlations between the brain’s default mode
network and previously knownAD pathophysiology patterns
have become more evident with the advances in functional
structural imaging techniques. Furthermore, development
of PET molecular imaging probes also makes it possible
to assess in vivo distribution of AD pathology within the
default mode network activity in living AD patients. Atrophy
measurements, [F-18]FDG PET and [F-18]FDDNP PET
studies point to the medial temporal cortex and posterior
cingulate gyrus as two areas of DMN with the earliest
pathological and functional changes. Cross-sectional PET
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Figure 6: [F-18]FDDNP minus [C-11]PIB results (yellow blobs) in the same patients with AD as statistical parameter mapping (SPM)
projections superimposed on a standardized magnetic resonance imaging brain template in the three orthogonal right sagittal (upper left),
coronal (upper right), and axial (lower left) views (P < .05 (FWE); corrected, k = 100). Adapted and reprinted with permission from Shin
et al. [25] [Copyright (2010) Neuroimage].
studies show initial [F-18]FDDNP binding in the medial
temporal cortex and spreading stepwise to the other areas
of DMN. [C-11]PIB determinations reveal a single pattern
of binding within DMN which does not include the medial
temporal cortex. This pattern is present in on-off fashion
in control and MCI subjects [46]. Multitracer PET imaging
determinations using both [F-18]FDDNP and [C-11]PIB in
the same subjects, with and without AD showed overlaps
between [C-11]PIB-binding patterns and [F-18]FDDNP
binding patterns within the brain’s default mode network.
However, it also demonstrated a critical discrepancy found
in the medial temporal cortex where [F-18]FDDNP binding
is the highest but [C-11]PIB binding is negligible. Moreover,
while [F-18]FDDNP shows the expected pattern of disease
progression, [C-11]PIB shows uniform patterns of distri-
bution throughout the DMN at various stages of disease
evolution. Because marked AD pathology (demonstrated by
postmortem histopathology) and atrophy (demonstrated by
T1-weighted MR imaging) have their earliest manifestation
in the medial temporal cortex, [C-11]PIB binding in the
DMN is inconsistent with its purported specificity for beta-
amyloid aggregates.
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